Alessandra Ferro

机构：Istituto Oncologico Veneto · ORCID：0000-0002-1163-3765

发表论文 90 篇 · 总被引 725 次 · h-index 16

代表论文

• Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial (2022 · Journal of Thoracic Oncology · 被引 70)
• The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies (2024 · Critical Reviews in Oncology/Hematology · 被引 69)
• First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study (2021 · The Oncologist · 被引 64)
• Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome (2021 · Translational Lung Cancer Research · 被引 47)
• Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis (2024 · Journal of Thoracic Oncology · 被引 46)
• Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives (2024 · Critical Reviews in Oncology/Hematology · 被引 30)